Citius Oncology, Inc. (CTOR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Oncology, Inc., a Delaware corporation and emerging growth company, on September 19, 2025. The report details corporate actions taken on the same date regarding equity securities and stock incentive plans.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on corporate governance and equity transactions rather than financial performance results.
Material Changes and Corporate Actions
- Unregistered Sales of Equity Securities (Item 3.02): The Company issued warrants to a financial advisor to purchase up to 360,000 shares of common stock.
- Exercise Price: $2.1875 per share.
- Exercise Date: March 10, 2026.
- Expiration Date: March 10, 2031.
- Transaction Type: Private placement pursuant to Section 4(a)(2) of the Securities Act of 1933.
- Stock Incentive Plan Amendment (Item 5.02): The Board of Directors approved an amendment to the 2024 Omnibus Stock Incentive Plan.
- Change: Increased the authorized number of shares reserved for issuance from 15,000,000 to 30,000,000 shares.
- Other Terms: No other changes were made to the plan.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosure of the equity issuance and plan amendment.
Key Facts for Investor Verification
- Verify the potential dilution impact of the 360,000 warrants issued at $2.1875 per share.
- Confirm the total number of shares now available for future employee compensation following the increase to 30,000,000 shares in the 2024 Plan.
- Review the full text of the 2024 Omnibus Stock Incentive Plan amendment (Exhibit 10.1) for specific vesting or eligibility criteria.
- Check the Company's current cash position to assess the ability to fund operations given the lack of reported revenue in this filing.